The three high-tech companies join forces in MDG to develop customized, cost-effective diagnostic and therapeutic solutions for precision medicine with few side effects and to promote their widespread application. Our approximately 300 highly specialized employees work together on innovative developments in precision medicine in order to make their pioneering application possible for as many patients as possible.

 

Firstly, the focus is on maximum efficiency in molecular diagnostics: to this end, BIOTYPE has developed the MODAPLEX system, a laboratory device for the automated multi-gene analysis of molecular biomarker signatures. Secondly, with ROTOP Pharmaka we are pursuing targeted theranostics with radioisotopes. It combines imaging diagnostics down to the molecular level of a tumor with the targeted therapy of precisely these tumor cells. And thirdly, with qualitype, we are focusing on consistent digitalization and data integration in the healthcare sector.